CASE REPORT

Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma

Takahiro Kametani, Yuichiro Otani, Toshikazu Ohigashi, Tadahiko Kubo, Tomohiko Sakuda, Daisuke Furuta, Yayoi Ito, Yuya Shigenobu, Masaki Kakimoto, Akihiro Kawahara, Yuka Kikuchi, Tomoki Kobayashi, Daisuke Miyamori, Nobusuke Kishikawa, Keishi Kanno, and Masanori Ito

Abstract:
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous manifestations during treatment for recurrent extraosseous mucinous chondrosarcoma. Computed tomography revealed large-vessel vasculitis, splenomegaly, and pulmonary interstitial changes. Treatment with prednisolone was successful. Because sarcoma is a rare disease, this case is valuable for showing clinicians that G-CSF preparations could cause aortitis regardless of the patient’s underlying diseases or therapeutic pharmacological backgrounds.

Key words: G-CSF, aortitis, pegfilgrastim, sarcoma

(Intern Med 60: 1311-1315, 2021)  
(DOI: 10.2169/internalmedicine.5913-20)

Introduction

Granulocyte colony-stimulating factor (G-CSF) preparations are commonly used to prevent and treat neutropenia caused by cancer chemotherapy. Meta-analyses of randomized controlled trials of G-CSFs as primary prophylaxis against febrile neutropenia have demonstrated significant reductions in the rates of short-term all-cause mortality, as well as rates of infection-related mortality, in patients with solid tumors and malignant lymphoma (1, 2). A meta-analysis of 59 randomized controlled trials demonstrated that systemic cancer chemotherapy with primary adjunct G-CSF treatment was associated with a significantly greater intensity of the effect of the delivered chemotherapy doses and with greater relative and absolute risk reductions in all-cause mortality rates than was chemotherapy without adjunct G-CSF treatment over a long period (3). As for drug safety, Teshima et al. reported that according to the results of their post-marketing use survey in Japan, the rate of overall adverse effects was 7.47%; these effects included lumbago (3.84%), fever (1.62%), and bone pain (0.61%), and most were not serious and seemed to be ameliorated by the discontinuation of G-CSF treatment (4).

However, a few cases with serious adverse effects, such as interstitial pneumonia and extramedullary hematopoietic splenic rupture, have been reported after the administration of G-CSF (5, 6). Pegfilgrastim, a relatively new G-CSF used to prevent febrile neutropenia, is a modified protein consisting of methoxy polyethylene glycol (PEG) molecular chains attached to a Met1 amino group of genetic recombinant filgrastim whose renal excretion is reduced and whose effects are prolonged (7). In Japan, pegfilgrastim is approved for use only to prevent febrile neutropenia after chemotherapy. To optimize its pharmacological effect and prevent adverse effects, the use of pegfilgrastim is restricted to patients at...
high risk for febrile neutropenia at least 24 hours after a course of chemotherapy. Over the past two decades, authors have reported cases of aortitis induced by G-CSF preparations such as filgrastim, lenograstim, and pegfilgrastim (8, 9). Oshima et al., using the Japanese Adverse Drug Event Report database, reported that G-CSF treatment is associated with an increased risk for aortitis (10).

We herein report a case of G-CSF-induced aortitis that coincided with lung injury, splenomegaly, and rash during treatment for extraosseous mucinous chondrosarcoma. This is a rare case of G-CSF induced aortitis occurred in a patient who was being treated for sarcoma and it is valuable for showing clinicians that G-CSF preparations could cause aortitis regardless of the patient’s underlying diseases or therapeutic pharmacological background.

Case Report

A 56-year-old man who was receiving treatment for the local recurrence of extraosseous mucinous chondrosarcoma on the right lower limb presented to our hospital because of an 8-day history of high fever, general fatigue, and a rash on the right lower limb. He had finished the first 4-day course of chemotherapy with 2-day adriamycin (25 mg/m² each) and four-day ifosfamide (2.8 g/m² each), followed 36 hours later by subcutaneous administration of pegylated G-CSF (3.6 mg), and he was discharged immediately. Four days later, the symptoms began.

On presentation, he did not appear ill, and he was alert and oriented. His body weight was 69.4 kg, and his height was 169 cm. His vital signs were as follows: blood pressure, 90/47 mm Hg; pulse rate, 95 beats/min; body temperature, 39.1°C; respiratory rate, 12/min; and oxygen saturation level, 99% on room air. A physical examination revealed palm-sized dark red-to-purplish indurated rashes with tenderness on the right cubital fossa and over the left knee socket (Fig. 1a, b). The surface lymph nodes, liver, and spleen were not palpable. The initial laboratory data revealed the following: a white blood cell count of 15,780/μL (90.0% segmented neutrophils, 7.0% stab neutrophils 1.0% monocytes, 2.0% lymphocytes, and 0% atypical lymphocytes, visually confirmed), hemoglobin level of 11.8 g/dL, platelet count of 109,000/μL, and serum C-reactive protein level of 38.77 mg/dL. Table lists the other laboratory data.

The results of antigen tests for influenza virus were negative. Two sets of blood culture were conducted. Computed tomography (CT) without contrast media revealed inflammatory changes in the soft tissue surrounding the aorta, partial reticular change and ground-glass opacities scattered throughout both lungs, and splenomegaly (Fig. 2).

Because he was immunocompromised, we diagnosed systemic inflammatory response syndrome and acute renal failure caused by bacterial infection. We promptly administered 2 L of crystalloid infusion for resuscitation and empirical piperacillin/tazobactam as shown in Fig. 3. His renal function was restored rapidly, but high-grade fever persisted for 4 days, as did the inflammatory markers, despite antibiotic treatment. However, this patient did not appear ill, and his food intake did not decrease during the first 4 days after his admission to this hospital. Furthermore, even with a high-grade fever (>40°C), his pulse rate had stayed in the range of 60/min to 70/min, which represented relative bradycardia, which in turn has been considered a characteristic of drug-related fever (11). A blood culture yielded negative results, as did serological tests (including cytomegalovirus antigen and autoantibodies); thus, we diagnosed aortitis resulting from G-CSF administration.

Because of concerns about the high-grade fever and the pulmonary findings, we initiated treatment with prednisolone, 60 mg (1 mg/kg) orally on the fourth day of hospitalization. His fever resolved within the day, followed by a rapid improvement in his general condition and laboratory data. The rash had improved simultaneously, although the skin discoloration remained. Six days after initiating prednisolone, we tapered the dosage to 40 mg and discharged the patient on day 18 (Fig. 3). At the 3-month follow-up visit, the patient remained well with the prednisolone dose of 7.5 mg/day, which was discontinued 3 months later.

Discussion

As in other immunocompromised patients after the administration of anticancer drugs, we had to rule out vasculitis secondary to infections before diagnosing the drug-induced aortitis, since infectious disease was strongly associated with systemic vasculitis, including aortitis (12). Hence, it might be important in such patients to evaluate them for common infectious diseases that are often overlooked—not only bacterial bloodstream infections but also tuberculosis, syphilis, viral hepatitis, and human immunodeficiency virus—that are known causes of vasculitis before G-CSF-induced
Table. Laboratory Data on Admission.

| Complete blood count | Serological test | Urine test |
|----------------------|------------------|------------|
| WBC 15,780 x 10^9/µL | CRP 38.77 mg/dL | occult blood 2+ |
| N-Stab 7 % | IgG 828 mg/dL | ketone negative |
| N-Seg 90 % | IgA 327 mg/dL | glucose negative |
| Eosino 0 % | IgM 103 mg/dL | protein 1+ |
| Baso 0 % | IgE 53 mg/dL | Urinary sediment |
| Mono 1 % | CH50 >60 | RBC <4 /HPF |
| Lymph 2 % | C3 162 mg/dL | WBC <4 /HPF |
| RBC 442 x 10^6/µL | C4 45 mg/dL | Squamous cell 0-1 /HPF |
| Hemoglobin 11.8 g/dL | sIL-2R 1,922 U/mL | cast positive |
| Platelet 109 x 10^9/µL | ANA <80 | β2 microglobulin 18.7 mg/dL |

Biochemistry:
- PR3-ANCA <1.0 U/mL
- MPO-ANCA <1.0 U/mL
- anti ssDNA 2.5 AU/mL
- anti dsDNA <1.2 IU/mL
- ASO 38 IU/mL
- ASK ×320
- PCT 0.58 ng/mL
- IGRA negative
- RPR <1.0
- TPHA 0
- HCV Ab 0.03
- HBs Ag 0 IU/mL
- CMV IgG 64 UA/mL
- CMV IgM negative
- ESR 114 mm/hr

Other findings:
- Creatinine 2.29 mg/dL
- Na 139 mmol/L
- K 3.7 mmol/L
- Cl 101 mmol/L
- Blood Sugar 159 mg/dL
- HbA1c 6.4 %

In this case, pegfilgrastim was administered 36 hours after the completion of the first cycle of AI (adriamycin, ifosfamide) chemotherapy, and a series of symptoms had begun 4 days later. Most cases of G-CSF-induced aortitis had been reported to occur 1 to 15 days after the administration of G-CSF, and a few cases were reported to develop 1 month to 1 year later (8, 10). This variation in the latent period, which could interfere with the clinical diagnosis, might result from pharmacodynamic and pharmokinetic factors such as the type and amount of G-CSF used, type of the preceding chemotherapy, and individual physiological differences. In fact, pegfilgrastim and lipegfilgrastim, which both have a longer half-life and produce equivalent effects with fewer administrations, have been most often reported as the drug causing aortitis (8-10). It is of interest that this condition has been reported more often in women than in men, although more detailed cases and epidemiological studies are needed to prove that G-CSF-induced aortitis is indeed more common in women.

Searching on web, G-CSF-induced aortitis in a patient being treated for sarcoma was thus found to be extremely rare. One reason why no cases of G-CSF-induced aortitis were previously reported in patients with sarcomas might be due to the low absolute number of such patients. Ogura et al. reported that according to a nationwide organ-specific cancer...
registry for bone and soft tissue tumors in Japan, the number of patients with sarcomas in 2012 was 1,598, which is an extremely low proportion of the 865,238 cases of all cancers (15, 16). We believe that this case report, which concerns an orthopedic cancer, is important because the biological evidence that the administration of G-CSF could provoke aortitis is still lacking.

Although this patient did not exhibit any pulmonary manifestations, the lung interstitial changes found on CT seemed critical and warranted the administration of steroids, since there had been many reports of G-CSF-related pulmonary toxicity, which in some cases progressed to acute respiratory distress syndrome and to death (17-19). In a review of 20 cases of interstitial pneumonia secondary to treatment with G-CSF, Niitsu et al. reported that three patients died of respiratory and multiple organ failure; consequently, they emphasized the importance of starting steroid pulse therapy as early as possible when the diagnosis is made (20).

Although the skin lesions that this patient exhibited were not histologically confirmed, we speculated, from their macroscopic appearance, that they represented neutrophilic eccrine hidradenitis, which is neutrophilic dermatosis characterized by the sudden onset of erythematous papules or plaques with a neutrophilic infiltrate around eccrine glands, together with necrosis of these structures. Rising concentrations of the cytotoxic agents in sweat are thought to be the mechanism of neutrophilic eccrine hidradenitis, and doxorubicin is known to be one of the common causative substances (21). It is of interest that several such cases have been reported to be associated with the administration of G-CSF, and one of them occurred in patients who received pegfilgrastim after AI chemotherapy (22, 23).

Without any guidelines available for the treatment of drug-induced aortitis, we set the initial dose of prednisolone as 60 mg, administered it orally, according to the Guideline for Management of Vasculitis Syndrome (Japanese Circula-
tion Society 2008) for the diagnosis of giant cell arteritis (24). However, several cases of G-CSF-induced aortitis that remitted without the administration of prednisolone have been reported. We think that the degree of inflammatory response might vary in individual cases, and so the clinical decision of whether to administer prednisolone must be individualized. In our patient, prednisolone treatment was necessary because of sustained high-grade inflammatory markers and interstitial changes in the lungs.

In summary, we herein described a case of G-CSF-induced aortitis that coincided with lung injury, splenomegaly, and rash during treatment for extraosseous mucinous chondrosarcoma. The patient required PSL administration because of sustained high grade fever. The response to the treatment with PSL was good, and the patient had recovered without any sequelae. It has been almost 30 years since filgrastim was introduced to the market. However, G-CSF induced aortitis has not been well recognized. We speculate that one reason for this might be the lack of algorithm to predict patients at high risk to present this condition. Secondly, there is lack of specific signs and symptoms. In addition, as we described above, the condition sometimes subsides without the administration of steroids or immuno-suppressants which are usually indispensable for the treatment of other types of vasculitis syndrome. Therefore, we speculate that many cases of G-CSF induced may have been overlooked. This case report might be one type of supportive evidence of G-CSF induced aortitis, however, it is necessary to collect and examine future cases regarding what kind of patients: sex, races, age etc., are likely to present with aortitis due to G-CSF.

The authors state that they have no Conflict of Interest (COI).

References

1. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25: 3158-3167, 2007.
2. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325: 164-170, 1991.
3. Lyman GH, Dale DC, ulakova EC, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24: 2475-2484, 2013.
4. Teshima T, Takigawa N, Makita Y, et al. Results of a drug use survey of filgrastim biosimilar. Jpn J Cancer Chemother 44: 775-782, 2017.
5. Masood N, Shaikh AJ, Memon WA, et al. Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature. Cases J 1: 418, 2008.
6. Azoulay E, Attalah H, Harf A, et al. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality?: systematic review of clinical case reports and experimental data. Chest 120: 1695-1701, 2001.
7. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 23 (8 Pt 2): 3S-8S, 2003.
8. Taimen K, Heino S, Kohonen I, et al. Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review. Rheumatol Adv Prac 4: 2020.
9. Shirai T, Komatsu H, Sato H, et al. Migratory aortitis associated with granulocyte-colony-stimulating factor. Intern Med 59: 1559-1563, 2020.
10. Oshima Y, Takahashi S, Tani K, et al. Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database. Cytokine 119: 47-51, 2019.
11. Mackowiak PA, LeMaistre CF. Drug fever: a critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med 106: 728, 1987.
12. Belizna CC, Hamidou MA, Levesque H, et al. Infection and vasculitis. Rheumatology (Oxford) 48: 475-482, 2009.
13. Pagnoux C, Cohen P, Guillevin L. Vasculitides secondary to infections. Clin Exp Rheumatol 24 (2 Suppl 41): S71-S81, 2006.
14. Lardieri A, McCulley L, Christopher Jones S, et al. Granulocyte colony-stimulating factors and aortitis: a rare adverse event. Am J Hematol 93: E333-E336, 2018.
15. Ogura K, Hiashi T, Kawai A. Statistics of soft-tissue sarcoma in Japan: report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22: 133-143, 2017.
16. Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Ministry of Health, Labour and Welfare, National Cancer Registry).
17. Sakai C, Nakaseko C, Takagi T. Acute respiratory failure associated with G-CSF-induced leukocyte recovery in three patients with preceding infection. Kansenshogaku Zasshi 71: 1080-1084, 1997 (in Japanese, Abstract in English).
18. Lisukov IA, Kriuchkova IV, Kulagin AD, et al. The adult respiratory distress syndrome during the recovery of the neutrophil level after autologous bone marrow transplantation. Ter Arkh 70: 78-79, 1998.
19. Okubo Y, Nakazawa K. Recombinant G-CSF, and the interstitial pneumonia during MACOP-B therapy in two cases of non-Hodgkin’s lymphoma. RinshoKetsueki 34: 473-477, 1993 (in Japanese, Abstract in English).
20. Niitsu N, Iki S, Muroi K, et al. Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96. Br J Cancer 76: 1661-1666, 1997.
21. Fitzpatrick’s Dermatology 9th ed. McGraw Hill, 2019: 3483.
22. Bachmeyer C, Aractingi S. Neutrophilic eccrine hidradenitis. Clin Dermatol 18: 319-330, 2000.
23. Bachmeyer C, Chaibi P, Aractingi S. Neutrophilic eccrine hidradenitis induced by granulocyte colony-stimulating factor. Br J Dermatol 139: 354-355, 1998.
24. JCS Joint Working Group. Guideline for management of vasculitis syndrome (JCS 2008). Circ J 75: 474-450, 2011.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).